Literature DB >> 18699764

Current concepts on the surgical and medical management of osteosarcoma.

Herrick J Siegel1, Joseph G Pressey.   

Abstract

Although advances have been made in both surgical and medical management of patients with osteosarcoma, the overall survival of patients with osteosarcoma has remained constant, with no substantial improvement in the past 15 years. Advances in imaging have had a substantial impact on surgical planning and staging. These advances have, in turn, had a major impact on the surgeon's ability to perform limb-sparing surgery. Surgical techniques have improved in terms of instrumentation, modularity of implants and availability. Limb salvage has proven to be an acceptable method of treatment both with respect to oncologic and functional outcome in those patients where a wide resection may be achieved. The use of massive allografts has been largely replaced with the use of modern oncologic endoprostheses. Biologic targets that will enable new therapies to have maximum effect on tumor cells while minimizing toxicity to the host tissues need to be identified.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18699764     DOI: 10.1586/14737140.8.8.1257

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  28 in total

1.  Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines.

Authors:  Zhenfeng Duan; Edwin Choy; David Harmon; Cao Yang; Keinosuke Ryu; Joseph Schwab; Henry Mankin; Francis J Hornicek
Journal:  Mol Cancer Ther       Date:  2009-07-28       Impact factor: 6.261

2.  MiR-26a inhibits stem cell-like phenotype and tumor growth of osteosarcoma by targeting Jagged1.

Authors:  J Lu; G Song; Q Tang; J Yin; C Zou; Z Zhao; X Xie; H Xu; G Huang; J Wang; D-F Lee; R Khokha; H Yang; J Shen
Journal:  Oncogene       Date:  2016-06-06       Impact factor: 9.867

3.  IRX1 hypomethylation promotes osteosarcoma metastasis via induction of CXCL14/NF-κB signaling.

Authors:  Jinchang Lu; Guohui Song; Qinglian Tang; Changye Zou; Feng Han; Zhiqiang Zhao; Bicheng Yong; Junqiang Yin; Huaiyuan Xu; Xianbiao Xie; Tiebang Kang; YingLee Lam; Huiling Yang; Jingnan Shen; Jin Wang
Journal:  J Clin Invest       Date:  2015-03-30       Impact factor: 14.808

4.  The expressions of CD133, ALDH1, and vasculogenic mimicry in osteosarcoma and their clinical significance.

Authors:  Zhengqi Bao; Zenong Cheng; Damin Chai
Journal:  Int J Clin Exp Pathol       Date:  2018-07-01

5.  Glycogen synthase kinase-3β, NF-κB signaling, and tumorigenesis of human osteosarcoma.

Authors:  Qing-Lian Tang; Xian-Biao Xie; Jin Wang; Qiong Chen; An-Jia Han; Chang-Ye Zou; Jun-Qiang Yin; Da-Wei Liu; Yi Liang; Zhi-Qiang Zhao; Bi-Cheng Yong; Ru-Hua Zhang; Qi-Sheng Feng; Wu-Guo Deng; Xiao-Feng Zhu; Binhua P Zhou; Yi-Xin Zeng; Jing-Nan Shen; Tiebang Kang
Journal:  J Natl Cancer Inst       Date:  2012-04-24       Impact factor: 13.506

6.  Targeting the anaphase-promoting complex/cyclosome (APC/C)- bromodomain containing 7 (BRD7) pathway for human osteosarcoma.

Authors:  Kaishun Hu; Dan Liao; Wenjing Wu; An-Jia Han; Hui-Juan Shi; Fen Wang; Xin Wang; Li Zhong; Tingmei Duan; Yuanzhong Wu; Jingying Cao; Jianjun Tang; Yi Sang; Li Wang; Xiaobin Lv; Shuangbing Xu; Ru-Hua Zhang; Wu-Guo Deng; Sheng-Ping Li; Yi-Xin Zeng; Tiebang Kang
Journal:  Oncotarget       Date:  2014-05-30

7.  Poly(lactic-co-glycolic acid) nanoparticles conjugated with CD133 aptamers for targeted salinomycin delivery to CD133+ osteosarcoma cancer stem cells.

Authors:  Miaozhong Ni; Min Xiong; Xinchao Zhang; Guoping Cai; Huaiwen Chen; Qingmin Zeng; Zuochong Yu
Journal:  Int J Nanomedicine       Date:  2015-03-31

8.  Determination of the apoptotic index in osteosarcoma tissue and its relationship with patients prognosis.

Authors:  Xing Wu; Biao Cheng; Zheng-Dong Cai; Lie-Ming Lou
Journal:  Cancer Cell Int       Date:  2013-06-04       Impact factor: 5.722

9.  Role of relaxin-2 in human primary osteosarcoma.

Authors:  Jinfeng Ma; Min Niu; Wenjiu Yang; Lina Zang; Yongming Xi
Journal:  Cancer Cell Int       Date:  2013-06-10       Impact factor: 5.722

10.  Down-regulation of S100A9 inhibits osteosarcoma cell growth through inactivating MAPK and NF-κB signaling pathways.

Authors:  Si Cheng; Xi Zhang; Ning Huang; Quanhe Qiu; Ying Jin; Dianming Jiang
Journal:  BMC Cancer       Date:  2016-03-28       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.